Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges-Reference-Cited by-同舟云学术

Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges

Published:2024-06-06 Issue:3 Volume:85 Page:371-382
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Laokulrath Natthawadee¹²,Gudi Mihir²,Salahuddin Syed Ahmed³,Chong Angela Phek Yoon⁴,Ding Cristine⁵,Iqbal Jabed³^ORCID,Leow Wei Qiang³⁶,Tan Benjamin Yongcheng³^ORCID,Tse Gary⁷,Rakha Emad⁸^ORCID,Tan Puay Hoon²⁹^ORCID

Affiliation:

1. Department of Pathology, Siriraj Hospital Mahidol University Bangkok Thailand

2. Department of Pathology and Laboratory Medicine KK Women's and Children's Hospital Singapore

3. Department of Anatomical Pathology Singapore General Hospital Singapore

4. Department of Pathology Sengkang General Hospital Singapore

5. Division of Anatomical Pathology Changi General Hospital Singapore

6. Duke‐NUS Medical School Singapore

7. Department of Anatomical and Cellular Pathology, Prince of Wales Hospital The Chinese University of Hong Kong Shatin Hong Kong

8. Cellular Pathology Department, School of Medicine University of Nottingham Nottingham UK

9. Luma Medical Centre Singapore

Abstract

Human epidermal growth factor receptor 2 (HER2)‐enriched breast cancer benefits significantly from anti‐HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti‐HER2 regimens. Recently, the emerging eligibility of patients with HER2‐low breast cancers for a novel HER2‐targeted antibody–drug conjugate (T‐DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0–1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/his.15213

Reference60 articles.

1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

2. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

3. UK recommendations for HER2 assessment in breast cancer: an update

4. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

5. Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low–Expressing Breast Cancer Cohort